This study wants to collect long-term follow-up data on delayed side effects after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Official registry: https://clinicaltrials.gov/study/NCT05201781 · Janssen Research & Development, LLC · enrollment listed as 295
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Cilta-cel. The registry lists allocation as na. This study wants to collect long-term follow-up data on delayed side effects after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
They plan to enroll about 295 people at 50 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Interventions: Cilta-cel
Primary outcome (registry wording): Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy
Study Contact
Participate-In-This-Study1@its.jnj.com
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
+ 22 sites outside the US on the same record
Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S.
NCT02682667 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.
NCT05137054 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life.
NCT05312255 · Official ClinicalTrials.gov record · Roswell Park Cancer Institute
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary